Combined IL- 2, agonistic CD3 and 4- 1BB stimulation preserve clonotype hierarchy in propagated non- small cell lung cancer tumor- infiltrating lymphocytes
Overview
The study compares TIL expansion methods. TIL 3.0 (IL-2 + anti-CD3 + anti-4-1BB) in G-Rex® expanded more TILs with better CD8+ enrichment and TCR diversity than standard IL-2. The REP phase also used GREX-10M.
What this paper found
Adding agonistic anti-CD3 and anti-4-1BB (urelumab) stimulation to high-dose IL-2 during initial culture expanded tumor-infiltrating lymphocytes (TIL) from all 16 resected non-small cell lung cancer tumors tested, compared with 62.5% using IL-2 alone. Fragments from each tumor were grown in parallel with both methods. The three-signal method (TIL 3.0) produced a median of 186.3 × 10^6 versus 18.5 × 10^6 TIL in a median of 14 versus 27.5 days, with 86.43% versus 29.67% CD8+ cells. Its TCR repertoire was broader (median 3032 versus 1046 clonotypes), more similar to the tumor, and retained more putative tumor-specific TCR (median 20.31% versus 6%). A subsequent rapid expansion protocol reduced that retention from a median of 19.22% to 6.322%.
Note: Preclinical study on resected tumor tissue. The authors note that the first-step TIL 3.0 output does not reach the cell numbers usually infused without a second expansion step, and that this step could be scaled up to reach higher numbers.
Altogether, these findings suggest that TIL 3.0 expands a NSCLC TIL product that better recapitulates the tumor when compared with products generated with TIL 1.0. — Parin Shah, Marie-Andrée Forget, Meredith L Frank, Peixin Jiang, Donastas Sakellariou-Thompson, Lorenzo Federico, Roohussaba Khairullah, Chantal Alexia Neutzler, Ignacio Wistuba, Chi-Wan B Chow, Yan Long, Junya Fujimoto, Shiaw-Yih Lin, Anirban Maitra, Marcelo V Negrao, Kyle Gregory Mitchell, Annikka Weissferdt, Ara A Vaporciyan, Tina Cascone, Jack A Roth, Jianjun Zhang, Boris Sepesi, Don L Gibbons, John V Heymach, Cara L Haymaker, Daniel J McGrail, Alexandre Reuben, Chantale Bernatchez, Journal for ImmunoTherapy of Cancer
Study details
- Authors
- Parin Shah, Marie-Andrée Forget, Meredith L Frank, Peixin Jiang, Donastas Sakellariou-Thompson, Lorenzo Federico, Roohussaba Khairullah, Chantal Alexia Neutzler, Ignacio Wistuba, Chi-Wan B Chow, Yan Long, Junya Fujimoto, Shiaw-Yih Lin, Anirban Maitra, Marcelo V Negrao, Kyle Gregory Mitchell, Annikka Weissferdt, Ara A Vaporciyan, Tina Cascone, Jack A Roth, Jianjun Zhang, Boris Sepesi, Don L Gibbons, John V Heymach, Cara L Haymaker, Daniel J McGrail, Alexandre Reuben, Chantale Bernatchez
- Institution
- Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA · Biologics Development, University of Texas MD Anderson Cancer Center, Houston, Texas, USA · Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA · Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA · Department of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA · Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA · Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
- Journal
- Journal for ImmunoTherapy of Cancer
- Year
- 2022
- G-Rex® model(s)
- G-Rex®10, G-Rex®10M
- Cell type(s)
- TIL Cells
- Application area
- Solid tumor
- Study phase
- Preclinical
How G-Rex® was used
For the TIL 3.0 first step, five tumor fragments per specimen were cultured in a G-Rex® 10 flask (Wilson Wolf Manufacturing) in 20 mL of medium with 6000 IU/mL IL-2, the 4-1BB agonist urelumab and anti-CD3 (OKT3), with half-medium changes every 3–4 days for up to 21 days. For the rapid expansion protocol, 0.5 × 10^6 TIL were seeded with 100 × 10^6 irradiated allogeneic PBMC in a GREX-10M in 40 mL of medium with anti-CD3 and 6000 IU/mL IL-2; 20 mL of medium was added on day 5, cultures were subcultured on day 7 with each flask topped to 100 mL, and cells were counted on day 14. The first step yielded a median of 186.3 × 10^6 TIL in a median of 14 days.
Note: The comparator method (TIL 1.0) grew fragments in standard 24-well plates, one fragment per well, with IL-2 alone.
Explore related
Full citation
Shah P, Forget MA, Frank ML, et al. Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. J Immunother Cancer. 2022;10(2):e003082.
Building a similar workflow?
Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.